

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
26 August 2021 (26.08.2021)



(10) International Publication Number
WO 2021/165452 A1

(51) International Patent Classification:

A61K 38/00 (2006.01) *C07K 14/82* (2006.01)
A61P 35/00 (2006.01) *G01N 33/574* (2006.01)
C12Q 1/6886 (2018.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/EP2021/054118

(22) International Filing Date:

19 February 2021 (19.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

20158306.9 19 February 2020 (19.02.2020) EP

(71) Applicants: **AELIN THERAPEUTICS** [BE/BE]; Gaston Geenslaan 1, 3001 Leuven (BE). **VIB VZW** [BE/BE]; Rijvisschestraat 120, 9052 Gent (BE). **KATHOLIEKE UNIVERSITEIT LEUVEN** [BE/BE]; KU Leuven R&D Waaistraat 6, bus 5105, 3000 Leuven (BE).

(72) Inventors: **CLAES, Filip, Maria, Hendrik**; Bevekomsestraat 60, 3360 Bierbeek (BE). **SCHYMKOWITZ, Joost**; Attenrodestraat 15, 3391 Meensel-Kiezegem (BE). **ROUSSEAU, Frederic**; Poverstraat 70, 1700 Sint-Martens-Bodegem (BE).

(74) Agent: **DE CLERCQ & PARTNERS**; Edgard Gevaertdreef 10a, 9830 Sint-Martens-Latem (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MOLECULES TARGETING MUTANT RAS PROTEIN

(57) Abstract: Aspects of the invention concern non-naturally occurring molecules configured to form an intermolecular beta-sheet with a human RAS protein mutated at position 12 or 13 and substantially not with wild-type human RAS protein, as well therapeutic applications thereof.

WO 2021/165452 A1